Abstracts Archive - Page 2259 of 2605 - ACR Meeting Abstracts

Abstract Number: 2612 • 2013 ACR/ARHP Annual Meeting
Epidemiology Of Cancer In Systemic Sclerosis. Systematic Review and Meta-Analysis Of Cancer Incidence, Predictors and Mortality
Tatiana Nevskaya¹, Shelly Chandran², Adrienne M. Roos¹, Christopher Pasarikovski¹, Amie T. Kron³, Cathy Chau⁴ and Sindhu R. Johnson⁵, ¹Medicine, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, ²Medicine, Toronto Scleroderma Research Program, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³Medicine, Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, ⁴Medicine, Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Medicine, Toronto Western Hospital, Toronto General Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada
Background/Purpose: To improve our understanding of the epidemiology of cancer in systemic sclerosis (SSc) by evaluating the incidence, prevalence, relative risk of overall and site-specific…
Abstract Number: 2613 • 2013 ACR/ARHP Annual Meeting
NF-κB Pathway Is Depleted In Phagocytes From Behçet´s Disease Patients Secondarily To Constitutive Phosphorylation Of The p65 Subunit
Sandro F. Perazzio^1,2, Paulo Vitor Soeiro Pereira³, Alexandre W.S. Souza^4,5, Antonio Condino-Neto³ and Luis Eduardo C. Andrade⁶, ¹Rheumatology, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ²Fleury Medicine and Health, Sao Paulo, Brazil, ³Immunology, ICB IV - Universidade de São Paulo, São Paulo, Brazil, ⁴University Medical Center Groningen, Groningen, Netherlands, ⁵Rheumatology Div/Dept of Med, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁶Rheumatology Division, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil
Background/Purpose: : Increased neutrophil activation has been previously shown in Behçet’s disease (BD) patients and it is unclear whether neutrophil activation occurs constitutively or if…
Abstract Number: 2614 • 2013 ACR/ARHP Annual Meeting
Plasma Of Active Behçet´s Disease Increases Oxidative Metabolism Profile Of Normal and Patients Phagocytes
Sandro F. Perazzio^1,2, Paulo Vitor Soeiro Pereira³, Alexandre W.S. Souza^4,5, Antonio Condino-Neto³ and Luis Eduardo C. Andrade⁶, ¹Rheumatology, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ²Fleury Medicine and Health, Sao Paulo, Brazil, ³Immunology, ICB IV - Universidade de São Paulo, São Paulo, Brazil, ⁴University Medical Center Groningen, Groningen, Netherlands, ⁵Rheumatology Div/Dept of Med, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁶Rheumatology Division, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil
Background/Purpose: Behçet’s disease (BD) exhibits several features suggestive of neutrophil hiperactivity. It is unclear whether neutrophil activation occurs constitutively or if it is secondary to…
Abstract Number: 2582 • 2013 ACR/ARHP Annual Meeting
Treatment Of Pulmonary Hypertension In Scleroderma Patients With Restricitive Lung Disease.Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma Cohort
Virginia D. Steen¹ and Robyn T. Domsic², ¹Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ²Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Trials of therapy in pulmonary hypertension(PH) have generally excluded patients with significant interstitial lung disease, but many patients with systemic sclerosis(SSc) and PH have…
Abstract Number: 2572 • 2013 ACR/ARHP Annual Meeting
An Atypical Cyclin-Dependent Kinase Mediates Fibrosis and Is a Novel Target In Scleroderma
Jun Wei¹, Roberta G. Marangoni², Wenxia Wang³, Jingang Huang⁴, Joerg H. W. Distler⁴ and John Varga⁵, ¹Rheumatology Division, Northwestern University, Chicago, IL, ²Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ³Medicine/Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁴Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Cyclin-dependent kinase 5 (CDK5), expressed primarily in the central nervous system, plays important roles in axonal guidance, dopaminergic signaling, neuronal migration, and pain sensing.…
Abstract Number: 2573 • 2013 ACR/ARHP Annual Meeting
The Role Of STAT-3 In The Development Of Pulmonary and Dermal Fibrosis
Mesias Pedroza¹, Sarah To¹, Anuh T. George¹, David J. Tweardy² and Sandeep K. Agarwal¹, ¹Medicine, Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX
Background/Purpose: Fibrosis is the accumulation of excessive extra-cellular matrix in tissues, leading to tissue damage. In systemic sclerosis, the trigger is postulated to be an…
Abstract Number: 2574 • 2013 ACR/ARHP Annual Meeting
Early Use of Prostacyclin Therapy Improves Transplant-Free Survival in Patients With Systemic Sclerosis-Related Pulmonary Arterial Hypertension Plus Interstitial Lung Disease
Elizabeth Volkmann¹, Rajan Saggar², Bryant Torres¹, Lynne Yoder², Robert Elashoff³, Rajeev Saggar⁴, Harsh Agrawal¹, Nabeel Borazan⁵, Sarah Thomas¹ and Daniel Furst¹, ¹Medicine, University of California, Los Angeles, Los Angeles, CA, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Biomath, University of California, Los Angeles, Los Angeles, CA, ⁴Critical Care Medicine, St. Joseph's Hospital and Medical Center, Phoenix, AZ, ⁵Medicine, Rheumatology UCLA, Los Angeles, CA
Background/Purpose: The leading causes of death in systemic sclerosis (SSc) are pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD). Use of PAH therapy in…
Abstract Number: 2575 • 2013 ACR/ARHP Annual Meeting
Utility Of Autoantibody Testing For Predicting Risk Of Pulmonary Arterial Hypertension: A Retrospective Analysis In Routine Autoantibody Laboratory
Masataka Kuwana¹, Yuichiro Shirai¹, Hidekata Yasuoka¹, Tsutomu Takeuchi¹ and Kenichi Masui², ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Department of Anesthesiology, National Defense Medical College, Tokorozawa, Japan
Background/Purpose: Pulmonary arterial hypertension (PAH) is an intractable complication of connective tissue disease (CTD). Current guidelines recommend early detection and intervention for improvement of outcomes.…
Abstract Number: 2576 • 2013 ACR/ARHP Annual Meeting
Epoprostenol Rescue Therapy In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension
Adrienne M. Roos¹, Christopher Pasarikovski¹, Amie T. Kron¹, John T. Granton², Peter Lee³, John Thenganatt⁴ and Sindhu R. Johnson⁵, ¹Medicine, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, ²Medicine, Toronto Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Lebovic Bldg, Mt. Sinai Hospital, Toronto, ON, Canada, ⁴Medicine, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Divisions of Respirology and Critical Care Medicine, Toronto, ON, Canada, ⁵Medicine, Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Epoprostenol has been demonstrated to improve hemodynamics, functional class, and six-minute walk distance (6MWD) in systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH…
Abstract Number: 2577 • 2013 ACR/ARHP Annual Meeting
Sex Disparities In Survival Of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension Patients
Christopher Pasarikovski¹, John T. Granton², Peter Lee³, Adrienne M. Roos¹, Amie T. Kron¹, Cathy Chau⁴ and Sindhu R. Johnson⁵, ¹Medicine, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, ²Medicine, Toronto Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Lebovic Bldg, Mt. Sinai Hospital, Toronto, ON, Canada, ⁴Medicine, Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Medicine, Toronto Western Hospital, Toronto General Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) associated pulmonary arterial hypertension (PAH) and idiopathic PAH (IPAH) are conditions with poor survival. There is evidence to suggest that sex…
Abstract Number: 2578 • 2013 ACR/ARHP Annual Meeting
Pulmonary Hypertension In Systemic Sclerosis: Clinical Classification and Pulmonary Hypertension Subtypes
Monica Mohile¹, Mary Lucas², Virginia D. Steen³, Thomas A. Medsger Jr.⁴ and Robyn T. Domsic⁵, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ³Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ⁴Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Pumonary hypertension (PH) is a significant complication of systemic sclerosis (SSc), with prevalence reports of 10-25%. Predictors of PH remain somewhat elusive. Our…
Abstract Number: 2579 • 2013 ACR/ARHP Annual Meeting
Recommendations For Screening and Detection Of Connective-Tissue Disease Associated Pulmonary Arterial Hypertension
Dinesh Khanna¹, Heather Gladue², John D. FitzGerald³, Richard N. Channick⁴, Lorinda Chung⁵, Oliver Distler⁶, Daniel Furst⁷, Eric Hachulla⁸, Marc Humbert^9,10,11, David Langleben^12,13, Stephen C. Mathai¹⁴, Rajeev Saggar¹⁵, Scott H. Visovatti¹⁶ and Vallerie McLaughlin¹⁷, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Medicine/Rheumatology, UCLA School Med Rehab #32-59, Los Angeles, CA, ⁴Pulmonary Hypertension Program, Massachusetts General Hospital, Boston, MA, ⁵Rheumatology, Stanford Univ Medical Center, Palo Alto, CA, ⁶Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁷Rheumatology, University of California in Los Angeles, Los Angeles, CA, ⁸Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ⁹AP-HP Hôpital Antoine Béclère, Clamart, France, ¹⁰Université Paris-Sud, Le Kremlin-Bicêtre, France, ¹¹NSERM U999, Centre Chirurgical Marie-Lannelongue, Le Plessis-Robinson, France, ¹²Cardiology Division, Jewish General Hospital, Montreal, QC, Canada, ¹³McGill University, Montreal, QC, Canada, ¹⁴Medicine, Johns Hopkins University, Baltimore, MD, ¹⁵Critical Care Medicine, St. Joseph's Hospital and Medical Center, Phoenix, AZ, ¹⁶Internal Medicine, Division of Cardiology, The University of Michigan, Ann Arbor, MI, ¹⁷Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI
Background/Purpose: Pulmonary arterial hypertension (PAH) affects up to 15% of patients with connective tissue diseases (CTD) and is one of the leading causes of mortality…
Abstract Number: 2580 • 2013 ACR/ARHP Annual Meeting
Does Mycophenolate Mofetil (MMF) Have An Effect On Pulmonary Hemodynamics? Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma (PHAROS) Cohort
Lesley Ann Saketkoo¹, Matthew R. Lammi², Jessica K. Gordon³, Paula Lauto⁴ and Virginia D. Steen⁵, ¹LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Pulmonary and Critical Care Medicine, LSU Health Sciences Center, New Orleans, LA, ⁵Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Does Mycophenolate Mofetil (MMF) have an effect on Pulmonary Hemodynamics? Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) CohortBackground/Purpose: Systemic…
Abstract Number: 2581 • 2013 ACR/ARHP Annual Meeting
Can Changes In NT-Probnp Predict Early Response To Therapy and Prognosis In Systemic Sclerosis Associated Pre-Capillary Pulmonary Hypertension?
Vincent Sobanski¹, Bernadette Lynch², Benjamin E. Schreiber³, Clive Handler⁴, Christopher P. Denton⁵ and John G. Coghlan⁶, ¹Department of Rheumatology, Royal Free Hospital, London, United Kingdom, ²Department of Rheumatology, The Royal Free Hospital, London, United Kingdom, ³Royal Free Hospital NHS Foundation Trust, National Pulmonary Hypertension Service, London, United Kingdom, ⁴Department of Pulmonary Hypertension, The Royal Free Hospital, London, United Kingdom, ⁵Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ⁶National Pulmonary Hypertension Service, The Royal Free Hospital NHS Foundation Trust, London, United Kingdom
Background/Purpose: Pulmonary hypertension (PH) is a severe complication of systemic sclerosis (SSc), affecting 5-12% of patients. Despite recent progress in treatment, prognosis remains poor. Early…
Abstract Number: 2583 • 2013 ACR/ARHP Annual Meeting
Long-Term Treatment With Endothelin Receptor Antagonist Increases Peripheral Blood Perfusion In Systemic Sclerosis Patients
Maurizio Cutolo¹, Barbara Ruaro², Elena Bernero², Francesca Ravera³, Giuseppe Zampogna³, Elisa Alessandri², Vanessa Smith⁴ and Alberto Sulli³, ¹Internal medicine, Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ³Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁴Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
Background/Purpose: Systemic sclerosis (SSc) is characterized by progressive impairment of the microvascular system and decrease of peripheral blood perfusion (PBP) (1-3). The vasoactive peptide endothelin-1…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].